Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Current Quarter	$-0.03	Next Quarter	$NA
Current Year	$-0.37	Next Year	$-0.18
QoQ Growth	NaN%	YoY Growth	+51.4%
3Y EPS CAGR	-34.7%	Target Price	$9.25
Consensus	Buy	Upside	+525.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RANI	$1.48	+0.68%	799.67K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RANI	$1.48	+0.7%	799.67K
3
4
5
6

RANI

RANI

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Rani Therapeutics Holdings Inc. Data in Excel

Get Rani Therapeutics Holdings Inc. Data in Excel